The Federal Patents Court in Munich upheld challenges brought by four generic rivals that the combination patent was invalid on salmeterol and fluticasone propionate, the drugs in Viani, also known as Seretide and Advair for asthma and chronic obstructive pulmonary disease.
The action follows similar dismissals of GSK’s patents in the UK and Ireland, at a time a number of generic rivals are seeking to launch versions of the medicine.
via ft.com
No comments:
Post a Comment